Why the study?
Does quinidine therapy alter the elimination and pharmacokinetics of digitoxin in healthy volunteers?
Does quinidine therapy alter the elimination and pharmacokinetics of digitoxin in healthy volunteers?
Quinidine significantly reduces the elimination of digitoxin, increasing its half-life and serum concentration without altering its volume of distribution.
Answers are grounded in this paper and cite their sources.
Quinidine may prolong digitoxin half-life; leaves open need for dose adjustment or outcome impact in patients.
Elevated serum digoxin concentrations and clinical toxicity have been reported in patients receiving quinidine. The present study was undertaken to ascertain whether a similar interaction occurs between quinidine and another cardiac glycoside, digitoxin, and if so to evaluate the pharmacokinetic basis in five healthy volunteers. In the presence of quinidine the serum digitoxin concentration was elevated, the mean digitoxin elimination half-life was increased from 87.8 +/- 11.6 to 218.3 +/- 20.6 h (mean +/- SEM) (p < 0.01), and mean total body clearance was reduced from 5.01 +/- 1.18 to 1.87 +/- 0.20 mL/h x kg (p < 0.052). No change was observed in the apparent volume of distribution or in the volume of the central compartment for digitoxin. The data suggest that the mechanism for this interaction is a reduction in elimination and not displacement of digitoxin from tissue binding sites.
No takes yet. Share an insight, caveat, or question.
Moshe Garty (1981) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: